LAB stock news · Standard BioTools Inc.
Get alerts for LAB
Follow Standard BioTools Inc. (LAB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LABFree on the App Store and Google Play, or on the web.
Standard BioTools Inc. shared news about a lawsuit connected to its merger with Treeline Biosciences.
Bad for LABStandard BioTools received 15 demand letters and faced 2 lawsuits over its merger voting papers. The legal challenges add uncertainty, making this negative for the company.
Standard BioTools Inc. says it will sell its Microfluidics business to ARCHIMED soon.
NeutralStandard BioTools agreed to sell its Microfluidics business, but gave no sale price or expected gains. The deal still needs to close, so the announcement does not change the company's outlook.
Standard BioTools Inc. has signed a new deal with Element Biosystems after ending its old agreement with Multiplex Bio.
NeutralLAB agreed to sell its mass cytometry business for $5.5 million, but it also agreed to pay a fee and still needs approvals. The story does not clearly change its outlook.